{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T22:41:52Z","timestamp":1648680112820},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"23-24","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1007\/s10354-008-0630-z","type":"journal-article","created":{"date-parts":[[2009,1,22]],"date-time":"2009-01-22T10:40:53Z","timestamp":1232620853000},"page":"702-706","source":"Crossref","is-referenced-by-count":0,"title":["Bisphosphonate und Kiefernekrose \u2013 eine zunehmende Herausforderung in der Palliativmedizin"],"prefix":"10.1007","volume":"158","author":[{"given":"Dora","family":"Beke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Pecherstorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"630_CR1","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"D Roodmann","year":"2004","unstructured":"Roodmann D. Mechanisms of bone metastasis. N Engl J Med, 350: 1655\u20131664, 2004","journal-title":"N Engl J Med"},{"key":"630_CR2","doi-asserted-by":"crossref","first-page":"6258","DOI":"10.1158\/1078-0432.CCR-06-0840","volume":"12","author":"JJ Body","year":"2006","unstructured":"Body JJ. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res, 12: 6258\u20136263, 2006","journal-title":"Clin Cancer Res"},{"key":"630_CR3","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","volume":"23","author":"N Kohno","year":"2005","unstructured":"Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol, 23: 3314\u20133321, 2005","journal-title":"J Clin Oncol"},{"key":"630_CR4","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","volume":"17","author":"RL Theriault","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol, 17: 846\u2013854, 1999","journal-title":"J Clin Oncol"},{"key":"630_CR5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"MF Gnant","year":"2007","unstructured":"Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol, 25: 820\u2013828, 2007","journal-title":"J Clin Oncol"},{"key":"630_CR6","first-page":"1322","volume":"92","author":"DY Graham","year":"1997","unstructured":"Graham DY, Malaty HM, Goodgame R. Primary amino-bisphosphonates: a new class of gastrotoxic drugs-comparison of alendronate and aspirin. Am J Gastroenterol, 92: 1322\u20131325, 1997","journal-title":"Am J Gastroenterol"},{"key":"630_CR7","doi-asserted-by":"crossref","unstructured":"G\u00f6l D. Persistency with oral bisphosphonates in cancer patients. Proc ASCO Abstr 8221, 2005","DOI":"10.1200\/jco.2005.23.16_suppl.8221"},{"key":"630_CR8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"R Marx","year":"2003","unstructured":"Marx R. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg, 61: 1115\u20131117, 2003","journal-title":"J Oral Maxillofac Surg"},{"key":"630_CR9","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","volume":"23","author":"A Bamias","year":"2005","unstructured":"Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol, 23: 8580\u20138587, 2005","journal-title":"J Clin Oncol"},{"key":"630_CR10","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood.V104.11.4933.4933","volume":"104","author":"V Kut","year":"2004","unstructured":"Kut V, Mehta J, Tariman J, Olsson A, Singhal S. Osteonecrosis of the jaw in myeloma patients receiving pamidronate or zoledronate. Blood, 104: 4933, 2004","journal-title":"Blood"},{"key":"630_CR11","first-page":"968","volume":"91","author":"MA Dimopoulos","year":"2006","unstructured":"Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica, 91: 968\u2013971, 2006","journal-title":"Haematologica"},{"key":"630_CR12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/annonc\/mdl163","volume":"17","author":"G Sanna","year":"2006","unstructured":"Sanna G, Preda L, Bruschini R, Cossu Rocca M, Ferretti S, Adamoli L, Verri E, Franceschelli L, Goldhirsch A, Nole F. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol, 17: 1512\u20131516, 2006","journal-title":"Ann Oncol"},{"key":"630_CR13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","volume":"353","author":"M Maerevoet","year":"2005","unstructured":"Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med, 353: 99\u2013102, 2005","journal-title":"N Engl J Med"},{"key":"630_CR14","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/annonc\/mdl294","volume":"17","author":"T Van den Wyngaert","year":"2006","unstructured":"Van den Wyngaert T, Huizing MT, Vermorken JB. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol, 17: 1197\u20131204, 2006","journal-title":"Ann Oncol"},{"key":"630_CR15","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","volume":"355","author":"JP Bilezikian","year":"2006","unstructured":"Bilezikian JP. Osteonecrosis of the jaw. Do bisphosphonates pose a risk? N Engl J Med, 355: 2278\u20132281, 2006","journal-title":"N Engl J Med"},{"key":"630_CR16","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","volume":"144","author":"SB Woo","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med, 144: 753\u2013761, 2006","journal-title":"Ann Intern Med"},{"key":"630_CR17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2141.2006.06230.x","volume":"134","author":"K Zervas","year":"2006","unstructured":"Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mihou D, Krikelis D, Terpos E. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol, 134: 620\u2013623, 2006","journal-title":"Br J Haematol"},{"key":"630_CR18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"JH Lin","year":"1996","unstructured":"Lin JH. Bisphosphonates: a rewiev of their pharmakokinetic properties. Bone, 18: 75\u201385, 1996","journal-title":"Bone"},{"key":"630_CR19","unstructured":"Chukwujindu J, Dolin P, Hoffmann-La Roche LTD. Welwyn Garden City, United Kingdom. ESMO, 2006"},{"key":"630_CR20","first-page":"2893","volume":"9","author":"D Santini","year":"2003","unstructured":"Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res, 9: 2893\u20132897, 2003","journal-title":"Clin Cancer Res"},{"key":"630_CR21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/jop.2006.2.1.7","volume":"2","author":"S Ruggiero","year":"2006","unstructured":"Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert M, Huryn JM, Toth B, Damato K, Valero V. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Practice, 2: 7\u201314, 2006","journal-title":"J Oncol Practice"},{"key":"630_CR22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000097876","volume":"117","author":"E Nastro","year":"2007","unstructured":"Nastro E, Musolino C, Allegra A, Oteri G, Cicciu M, Alonci A, Quartarone E, Alati C, De Ponte FS. Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol, 117: 181\u2013187, 2007","journal-title":"Acta Haematol"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-008-0630-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-008-0630-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-008-0630-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T22:57:07Z","timestamp":1589497027000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-008-0630-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":22,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s10354-008-0630-z","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}